Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer.
Benedetti R, Dell'Aversana C, De Marchi T, Rotili D, Liu NQ, Novakovic B, Boccella S, Di Maro S, Cosconati S, Baldi A, Niméus E, Schultz J, Höglund U, Maione S, Papulino C, Chianese U, Iovino F, Federico A, Mai A, Stunnenberg HG, Nebbioso A, Altucci L. Benedetti R, et al. Among authors: de marchi t. Cancers (Basel). 2019 Dec 16;11(12):2027. doi: 10.3390/cancers11122027. Cancers (Basel). 2019. PMID: 31888209 Free PMC article.
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics.
Chianese U, Papulino C, Passaro E, Evers TM, Babaei M, Toraldo A, De Marchi T, Niméus E, Carafa V, Nicoletti MM, Del Gaudio N, Iaccarino N, Randazzo A, Rotili D, Mai A, Cappabianca S, Mashaghi A, Ciardiello F, Altucci L, Benedetti R. Chianese U, et al. Among authors: de marchi t. Mol Metab. 2022 Oct;64:101561. doi: 10.1016/j.molmet.2022.101561. Epub 2022 Aug 6. Mol Metab. 2022. PMID: 35944897 Free PMC article.
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial.
Egelberg M, De Marchi T, Pekar G, Tran L, Bendahl PO, Tullberg AS, Holmberg E, Karlsson P, Farnebo M, Killander F, Nimeús E. Egelberg M, et al. Among authors: de marchi t. Mol Oncol. 2023 Oct;17(10):2029-2040. doi: 10.1002/1878-0261.13426. Epub 2023 Apr 19. Mol Oncol. 2023. PMID: 36975842 Free PMC article. Clinical Trial.
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Bosch A, Staaf J, Killander F, Niméus E. Sigurjonsdottir G, et al. Among authors: de marchi t. Breast Cancer Res. 2023 Oct 10;25(1):123. doi: 10.1186/s13058-023-01724-2. Breast Cancer Res. 2023. PMID: 37817263 Free PMC article.
Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.
Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trapman-Jansen AM, Foekens R, Look MP, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Debets R, Martens JW, Foekens JA, Umar A. Liu NQ, et al. Among authors: de marchi t. Mol Cell Proteomics. 2014 Jul;13(7):1814-27. doi: 10.1074/mcp.M113.037176. Epub 2014 Apr 17. Mol Cell Proteomics. 2014. PMID: 24742827 Free PMC article.
4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.
De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, Luider TM, Foekens JA, Martens JW, Umar A. De Marchi T, et al. Mol Oncol. 2016 Jan;10(1):24-39. doi: 10.1016/j.molonc.2015.07.004. Epub 2015 Aug 7. Mol Oncol. 2016. PMID: 26285647 Free PMC article.
52 results